





IFFIm Chair Report

Gavi Board Meeting

Cyrus Ardalan Chair, IFFIm Board of Directors Geneva, 28-29 November 2018

Treasury manager:





IFFIm Chair Report

AGENDA

IFFIm quick facts

Key figures

IFFIm's impact... catalytic to saving lives

Key update: building relationships

Key update: enhancing IFFIm's support Gavi

IFFIm quick facts

Strong donor support Capital markets activity

Strong credit rating

Accolades



IFFIm attracted over US\$ 6.5 billion of pledges from ten sovereign donors



IFFIm raised over US\$ 6 billion from investors worldwide through 33 transactions since 2006



Sound and prudential financial policies translates into a strong credit rating (AA/Aa1/AA)




Widely recognised for financial innovation, notably in pioneering socially responsible investments



Key figures

IFFIm disbursements



■ IFFIm is a major contributor to Gavi financing

- From 2006 through 2018 US\$ 2.6 billion
- Represents 18% of Gavi disbursements
- At a critical period after its implementation, IFFIm disbursed 53% of Gavi's total disbursement (2006-10)
- Capacity remains to provide Gavi with a reliable and stable source of funding

Funding for spectrum of Gavi initiatives

- Routine immunisation: funding enables developing countries to introduce and scale up routine immunisation faster
- HSS: flexible and predictable funding mobilised to help developing countries tackle the most pressing constraints on expanding immunisation coverage
- Strategic investments: funding when needed to combat measles, yellow fever, polio and tetanus



IFFIm's impact... catalytic to saving lives

- The impact of IFFIm as an incremental, long-term and flexible source of funding is significant
- The benefits have been far-reaching:
 - Accelerated the vaccination of at least 80 million children with DTP3
 - Provided more than 90% of initial Pentavalent funding contributing to a 75% price reduction to US\$ 0.88 per dose¹
 - Funded more than **US\$ 300 million to 37 countries** through Gavi's health system strengthening support
 - Quickly disbursed over US\$ 400 million to fund time-sensitive, large-scale lifesaving interventions and stockpiles

 $^{1}2006 - 2018$



Key update: building relationships

■ Middle East trip: UAE, Kuwait, Saudi Arabia

- Gavi and IFFIm viewed with great interest
- There is significant potential in the region
- Gavi has positive social impact in the region: 50% of its work is in OIC countries
- IFFIm considering issuing an Islamic Finance instrument in the region

Kuwait invited IFFIm and Gavi back for follow up meetings

- Recognized common principles on which relationships can be built and strengthened
- Identified influencers in the power circles in the country

Brazil is the newest donor to IFFIm

■ Powerful message for donors: alongside traditional donor countries, emerging economy countries, including BRICS, can and are playing important roles



Meeting with H.E. Marzouq Al-Ghanim, Speaker of the National Assembly of Kuwait



Key update: enhancing IFFIm's support to Gavi

INITIATIVE

PURPOSE AND IFFIM'S VALUE PROPOSITION

Financial commitments for market shaping

- Additional financial tool for Gavi to help secure favourable vaccine pricing and sustainable supply
- Predictability of funding

Supporting CCEOP

- Provide innovative financing support for CCEOP through themed IFFIm bonds or helping unlock other sources of capital
- Access to new funding / capital markets

Vaccine scale-up

- Utilise IFFIm's flexible funding capabilities to support Gavi's VIS
- Flexibility / frontloading of funds

Contingent pledges for outbreak response

- Pledges on stand-by that are activated upon occurrence of a disease outbreak to enable rapid deployment of funds
- Large funding capacity and access to new funding / capital markets









THANK YOU

Treasury manager:



www.iffim.org

2 Lambs Passage London EC1Y 8BB, United Kingdom Company limited by guarantee. Registered in England and Wales with number 5857343. Registered as a charity with number 1115413.

